Literature DB >> 16485904

Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.

Ute M Kent1, Hsia-Lien Lin, Danielle E Mills, Kelly A Regal, Paul F Hollenberg.   

Abstract

The oral contraceptive 17-alpha-ethynylestradiol (17EE) is a mechanism-based inactivator of cytochrome P450s (P450s) 2B1 and 2B6. Inactivation of P450s 2B1 and 2B6 in the reconstituted system by [3H]17EE resulted in labeling of the P450 apoprotein. Mass spectral analysis of 17EE-inactivated P450 2B1 showed an increase in the mass of the apoprotein by 313 Da, consistent with the mass of 17EE plus one oxygen atom. P450s 2B1 and 2B6 were inactivated with [3H]17EE and digested with CNBr. Separation of these peptides resulted in the identification of one major labeled peptide for each enzyme. N-Terminal sequencing of these peptides yielded the amino acid sequences PYTDAVIHEI (for P450 2B1) and PYTEAV (for P450 2B6) that corresponded to amino acids P347-M376 and P347-M365 in P450s 2B1 and 2B6, respectively. Electrospray ionization (ESI)-liquid chromatography-mass spectrometry (LC-MS) and matrix-assisted laser desorption ionization (MALDI)-MS analysis of the P450 2B1-derived peptide resulted in a mass of 3654 Da consistent with the mass of the P347-M376 peptide (3385 Da) plus a 268 Da 17EE adduct. Chemically reactive intermediates of 17EE that were generated during the metabolism of 17EE by P450s 2B1 and 2B6 were trapped with gluthathione (GSH). ESI-LC-MS/MS analysis of 17EE-GSH conjugates from the incubation mixtures indicated that P450s 2B1 and 2B6 generated different reactive 17EE intermediates that were responsible for the inactivation and protein modification or the formation of GSH conjugates by these two enzymes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16485904      PMCID: PMC2533710          DOI: 10.1021/tx050256o

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  39 in total

1.  Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver.

Authors:  I H Hanna; J R Reed; F P Guengerich; P F Hollenberg
Journal:  Arch Biochem Biophys       Date:  2000-04-01       Impact factor: 4.013

Review 2.  Protein adduct formation as a molecular mechanism in neurotoxicity.

Authors:  Richard M Lopachin; Anthony P Decaprio
Journal:  Toxicol Sci       Date:  2005-05-18       Impact factor: 4.849

3.  Reassessment of cytochrome P450 2B2: catalytic specificity and identification of four active site residues.

Authors:  S M Strobel; J R Halpert
Journal:  Biochemistry       Date:  1997-09-30       Impact factor: 3.162

4.  Mechanism-based inactivation of cytochrome P450 2B1 by 7-ethynylcoumarin: verification of apo-P450 adduction by electrospray ion trap mass spectrometry.

Authors:  K A Regal; M L Schrag; U M Kent; L C Wienkers; P F Hollenberg
Journal:  Chem Res Toxicol       Date:  2000-04       Impact factor: 3.739

5.  High-resolution crystal structure of cytochrome P450cam.

Authors:  T L Poulos; B C Finzel; A J Howard
Journal:  J Mol Biol       Date:  1987-06-05       Impact factor: 5.469

Review 6.  Mechanism-based inactivators as probes of cytochrome P450 structure and function.

Authors:  U M Kent; M I Juschyshyn; P F Hollenberg
Journal:  Curr Drug Metab       Date:  2001-09       Impact factor: 3.731

7.  Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450.

Authors:  P R Ortiz de Montellano; E A Komives
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

8.  Purification to homogeneity and characterization of a form of cytochrome P-450 with high specificity for benzo[alpha]pyrene from beta-naphthoflavone-pretreated rat liver microsomes.

Authors:  T Saito; H W Strobel
Journal:  J Biol Chem       Date:  1981-01-25       Impact factor: 5.157

9.  Cytochrome P-450-dependent oxidation of the 17 alpha-ethynyl group of synthetic steroids. D-homoannulation or enzyme inactivation.

Authors:  S E Schmid; W Y Au; D E Hill; F F Kadlubar; W Slikker
Journal:  Drug Metab Dispos       Date:  1983 Nov-Dec       Impact factor: 3.922

10.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity.

Authors:  P A Williams; J Cosme; V Sridhar; E F Johnson; D E McRee
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

View more
  11 in total

1.  Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene.

Authors:  Hsia-lien Lin; Haoming Zhang; Matthew J Pratt-Hyatt; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

Review 2.  Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

Authors:  Paul R Ortiz de Montellano
Journal:  Drug Metab Rev       Date:  2019-07-07       Impact factor: 4.518

3.  Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds.

Authors:  Hsia-Lien Lin; Haoming Zhang; Vyvyca J Walker; Jaime D'Agostino; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2017-07-11       Impact factor: 3.922

4.  The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir.

Authors:  Hsia-lien Lin; Jaime D'Agostino; Cesar Kenaan; Diane Calinski; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2013-07-25       Impact factor: 3.922

Review 5.  Targeting of the highly conserved threonine 302 residue of cytochromes P450 2B family during mechanism-based inactivation by aryl acetylenes.

Authors:  Haoming Zhang; Hsia-lien Lin; Cesar Kenaan; Paul F Hollenberg
Journal:  Arch Biochem Biophys       Date:  2010-09-15       Impact factor: 4.013

6.  Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates cytochrome P450 2D6 by protein adduction.

Authors:  Leslie D Nagy; Catherine S Mocny; Laura E Diffenderfer; David J Hsi; Brendan F Butler; Evan J Arthur; Kyle J Fletke; Jairam R Palamanda; Amin A Nomeir; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2011-03-21       Impact factor: 3.922

7.  Mechanism-based inactivation of CYP2B1 and its F-helix mutant by two tert-butyl acetylenic compounds: covalent modification of prosthetic heme versus apoprotein.

Authors:  Hsia-Lien Lin; Haoming Zhang; Kathleen R Noon; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2009-08-21       Impact factor: 4.030

8.  Formation of Both Heme and Apoprotein Adducts Contributes to the Mechanism-Based Inactivation of Human CYP2J2 by 17α-Ethynylestradiol.

Authors:  Hsia-Lien Lin; Haoming Zhang; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2018-03-30       Impact factor: 3.922

9.  Modification of serine 360 by a reactive intermediate of 17-alpha-ethynylestradiol results in mechanism-based inactivation of cytochrome P450s 2B1 and 2B6.

Authors:  Ute M Kent; Chitra Sridar; Greg Spahlinger; Paul F Hollenberg
Journal:  Chem Res Toxicol       Date:  2008-08-26       Impact factor: 3.739

10.  tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance.

Authors:  Haoming Zhang; Hsia-lien Lin; Vyvyca J Walker; Djemel Hamdane; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2009-08-31       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.